查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1298392

抗酸剂市场：按作用方式、製剂类型、分销渠道：2023-2032 年全球机会分析和行业预测

Antacids Market By Mechanism of Action, By Formulation Type, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 249 Pages | 商品交期: 2-3个工作天内

价格

2022年抗酸剂市场价值为66.7882亿美元，预计到2032年将达到90.6847亿美元，2023年至2032年的复合年增长率为3.1%。

Antacids Market-IMG1

抗酸剂是用于缓解胃灼热和消化不良的药物。这些药物通过减少胃分泌的盐酸量起作用。胃分泌盐酸进行消化。由于酸具有腐蚀性，粘膜屏障可以保护胃壁免受侵蚀。然而，与胃酸反流和粘膜屏障相关的问题可能会导致胃灼热。在这种情况下，抗酸剂用于中和胃中存在的酸，产生中性物质，例如水和盐。这可以减少胃酸并缓解胃灼热和消化不良的症状。

抗酸剂有许多不同类型，包括片剂和液体，它们的味道和强度各不相同。这些药物在中等剂量下是安全的，并且对轻微症状有效。抗酸剂中常见的成分包括氢氧化铝、氢氧化镁、碳酸钙和碳酸氢钠。一些抗酸剂也用于缓解胀气和腹胀，例如西甲硅油与碳酸钙的组合以及氢氧化镁与西甲硅油的组合。

全球抗酸剂市场的增长是由酸相关疾病的日益流行、非处方（OTC）抗酸剂的便利性和可用性以及自我用药患者数量的增加推动的。胃酸相关疾病包括胃酸分泌过多引起的各种胃肠道疾病，例如胃食管反流病(GERD)、消化性溃疡和消化不良。这些与酸相关的疾病的日益流行是抗酸剂市场的主要驱动力。例如，根据国家医学图书馆 2020 年的数据，超过 6000 万美国人每月至少经历一次胃灼热。

然而，过度使用抗酸剂会导致各种副作用并阻碍市场增长。例如，抗酸剂会影响体内钠、钾和钙等电解质水平。长期使用抗酸剂还会加重肾臟负担，导致肾结石和肾衰竭等问题。此外，欠发达国家人群对胃酸反流和胃食管反流病（GERD）等疾病和治疗的认识较低也是市场的主要製约因素。

另一方面，越来越多的製造商专注于开发各种具有成本效益且副作用很少的药物，预计将为市场增长提供利润丰厚的机会。例如，Alkem Laboratories 提供各种口味的 Omee MPS Liquids，如薄荷、橙子和 Saunfu，以及相同口味的 Omee Chua Tabs。这些抗酸剂的价格实惠，使其在发展中国家和发达国家得到越来越多的采用。

目录

第 1 章 简介

第二章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资口袋
  • 波特五力分析
    • 供应商的议价能力
    • 买方议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场动态
    • 促进者
      • 胃酸反流和胃食管反流病患病率增加
      • 轻鬆获得非处方抗酸剂
      • 老龄化人口对抗酸剂的需求猛增
    • 阻碍因素
      • 限制使用抗酸剂
      • 替代疗法的出现
    • 机会
      • 世界人口生活方式的快速变化
  • COVID-19 市场影响分析

4 抗酸剂市场（按作用机制）

  • 概述
    • 市场规模及预测
  • 全身抗酸剂
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 非全身性抗酸剂
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类

5. 抗酸剂市场，按製剂类型

  • 概述
    • 市场规模和预测
  • 药片
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 液体
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类

6. 抗酸剂市场（按分销渠道）

  • 概述
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 药店和零售药店
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类
  • 在线提供商
    • 主要市场趋势、增长动力和机遇
    • 市场规模/预测：按地区
    • 市场份额分析：按国家分类

7.按地区划分的抗酸剂市场

  • 概述
    • 市场规模/预测：按地区
  • 北美
    • 主要趋势和机遇
    • 市场规模和预测：按作用机制
    • 市场规模/预测：按配方类型
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
  • 欧洲
    • 主要趋势和机遇
    • 市场规模和预测：按作用机制
    • 市场规模/预测：按配方类型
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 欧洲其他地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
  • 亚太地区
    • 主要趋势和机遇
    • 市场规模和预测：按作用机制
    • 市场规模/预测：按配方类型
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 澳大利亚
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 韩国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 亚太其他地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
  • 拉丁美洲/中东/非洲
    • 主要趋势和机遇
    • 市场规模和预测：按作用机制
    • 市场规模/预测：按配方类型
    • 市场规模和预测：按分销渠道划分
    • 市场规模/预测：按国家
      • 巴西
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 沙特阿拉伯
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 南非
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分
      • 其他地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按作用机制
      • 市场规模/预测：按配方类型
      • 市场规模和预测：按分销渠道划分

第8章 竞争格局

  • 介绍
  • 关键成功策略
  • 10大公司产品图
  • 比赛仪表板
  • 比赛热图
  • 2022 年顶级公司定位

第九章公司简介

  • Bayer AG
  • Alkem Laboratories Ltd.
  • Cipla Ltd
  • Pfizer Inc.
  • WellSpring Pharmaceutical Corporation
  • Haleon plc
  • Prestige Consumer Healthcare Inc.
  • Reckitt Benckiser Group PLC
  • Infirst Healthcare Inc.
  • Abbott Laboratories
Product Code: A10281

The antacids market valued for $6,678.82 million in 2022 and is estimated to reach $9,068.47 million by 2032, exhibiting a CAGR of 3.1% from 2023 to 2032.

Antacids Market - IMG1

Antacid is a medication that is used to alleviate heartburn and indigestion. These medications act by reducing the amount of hydrochloric acid secreted in the stomach. The stomach secretes hydrochloric acid to carry out the digestion process. As the acid is corrosive, a mucous barrier protects the lining of the stomach from being eroded. However, acid reflux or issues associated with the mucous barrier can result in heartburn. This In such cases, antacids are used to neutralize the acid present in the stomach to produce a neutral substance, such as water or salt. This reduces the acidity in the stomach and relieves symptoms of heartburn and indigestion.

Antacids are available in various types of formulations such as tablets, liquids, and others, along with a range of flavors and strengths. These medications are safe to use in moderation and can be effective for mild symptoms. Common ingredients in antacids include aluminum hydroxide, magnesium hydroxide, calcium carbonate, and sodium bicarbonate. Some antacids are given in combination such as simethicone along with calcium carbonate or magnesium hydroxide and simethicone, which is used to relieve gas and bloating.

The growth of the global antacids market is driven increase in prevalence of acid-related conditions, convenience & accessibility of over-the-counter (OTC) antacids, and rise in number of patients engaging in self-medication. Acid-related conditions involve a range of gastrointestinal disorders that are caused by excessive secretion of gastric acid, such as gastroesophageal reflux disease (GERD), peptic ulcers, and dyspepsia. Increase in prevalence of these acid-related conditions acts as a major driver of the antacids market. For instance, according to the National Library of Medicine in 2020, more than 60 million Americans experience heartburn at least once a month.

However, excessive use of antacids leads to a range of side effects that potentially hinder the growth of the market. For instance, antacids may affect the levels of electrolytes in the body, such as sodium, potassium, and calcium. In addition, prolonged use of antacids can put strain on the kidneys, leading to problems such as kidney stones or renal failure. In addition, low awareness about acid reflux, gastroesophageal reflux disease (GERD), and other conditions and available treatment among the population of underdeveloped countries acts as a key restraint of the market.

On the contrary, increase in focus of manufacturers to develop cost-effective and wide range of medications with less side effects is expected to offer lucrative opportunities for the market growth. For instance, Alkem Laboratories offers Omee MPS liquid, which is available in a range of flavors such as mint, orange, and saunf as well as Omee Chewtabs, which are available in the same flavors. These antacids are affordable, and thus, have witnessed increased adoption in developing and developed countries.

In addition, people in underdeveloped countries are becoming aware about antacid medications available in the market and their use in managing acidity and other acid-related conditions. This is anticipated to boost the market during the forecast period. In addition, emerging countries in Asia-Pacific and LAMEA are characterized by presence of large population base along with rapid economic growth and increase in healthcare expenditure. All these factors are anticipated to increase the demand for antacids in these regions, thereby boosting the global market growth.

The global antacids market is segmented into medication type, formulation type, distribution channel, and region. By product, the market is bifurcated into systemic antacids and non-systemic antacids. On the basis of formulation type, it is categorized into tablet, liquids, and others. By distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the Abbott Laboratories, Pfizer Inc., Prestige Consumer Healthcare Inc., Cipla Ltd, Reckitt Benckiser Group PLC, Haleon plc, Bayer AG, Alkem Laboratories Ltd., WellSpring Pharmaceutical Corporation and Infirst Healthcare Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antacids market analysis from 2022 to 2032 to identify the prevailing antacids market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antacids market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antacids market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Mechanism of Action

  • Systemic Antacids
  • Non-systemic Antacids

By Formulation Type

  • Tablets
  • Liquids
  • Others

By Distribution channel

  • Hospital pharmacies
  • Drug stores and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Abbott Laboratories
    • Alkem Laboratories Ltd.
    • Bayer AG
    • Cipla Ltd
    • Haleon plc
    • Infirst Healthcare Inc.
    • Pfizer Inc.
    • Prestige Consumer Healthcare Inc.
    • Reckitt Benckiser Group PLC
    • WellSpring Pharmaceutical Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of acid reflux and GERD
      • 3.4.1.2. Easy availability of OTC antacids
      • 3.4.1.3. Surge in demand for antacids among geriatric population
    • 3.4.2. Restraints
      • 3.4.2.1. Limitations related to use of antacids
      • 3.4.2.2. Emergence of alternative treatments
    • 3.4.3. Opportunities
      • 3.4.3.1. Rapidly changing lifestyle of global population
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ANTACIDS MARKET, BY MECHANISM OF ACTION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Systemic Antacids
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Non-systemic Antacids
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: ANTACIDS MARKET, BY FORMULATION TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Tablets
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Liquids
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: ANTACIDS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug stores and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: ANTACIDS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Mechanism of Action
    • 7.2.3. Market size and forecast, by Formulation Type
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Mechanism of Action
      • 7.2.5.1.3. Market size and forecast, by Formulation Type
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Mechanism of Action
      • 7.2.5.2.3. Market size and forecast, by Formulation Type
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Mechanism of Action
      • 7.2.5.3.3. Market size and forecast, by Formulation Type
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Mechanism of Action
    • 7.3.3. Market size and forecast, by Formulation Type
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.1.3. Market size and forecast, by Formulation Type
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.2.3. Market size and forecast, by Formulation Type
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.3.3. Market size and forecast, by Formulation Type
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.4.3. Market size and forecast, by Formulation Type
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.5.3. Market size and forecast, by Formulation Type
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Mechanism of Action
      • 7.3.5.6.3. Market size and forecast, by Formulation Type
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Mechanism of Action
    • 7.4.3. Market size and forecast, by Formulation Type
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.1.3. Market size and forecast, by Formulation Type
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.2.3. Market size and forecast, by Formulation Type
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.3.3. Market size and forecast, by Formulation Type
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.4.3. Market size and forecast, by Formulation Type
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.5.3. Market size and forecast, by Formulation Type
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Mechanism of Action
      • 7.4.5.6.3. Market size and forecast, by Formulation Type
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Mechanism of Action
    • 7.5.3. Market size and forecast, by Formulation Type
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Mechanism of Action
      • 7.5.5.1.3. Market size and forecast, by Formulation Type
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Mechanism of Action
      • 7.5.5.2.3. Market size and forecast, by Formulation Type
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Mechanism of Action
      • 7.5.5.3.3. Market size and forecast, by Formulation Type
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Mechanism of Action
      • 7.5.5.4.3. Market size and forecast, by Formulation Type
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Bayer AG
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Alkem Laboratories Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Cipla Ltd
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Pfizer Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. WellSpring Pharmaceutical Corporation
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Haleon plc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Prestige Consumer Healthcare Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Reckitt Benckiser Group PLC
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Infirst Healthcare Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. Abbott Laboratories
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 02. ANTACIDS MARKET FOR SYSTEMIC ANTACIDS , BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. ANTACIDS MARKET FOR NON-SYSTEMIC ANTACIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 05. ANTACIDS MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. ANTACIDS MARKET FOR LIQUIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. ANTACIDS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 09. ANTACIDS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. ANTACIDS MARKET FOR DRUG STORES AND RETAIL PHARMACIES , BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ANTACIDS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ANTACIDS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 18. U.S. ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 21. CANADA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. UK ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 37. UK ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 40. ITALY ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. CHINA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 56. CHINA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. INDIA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 59. INDIA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 60. INDIA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. LAMEA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 74. BRAZIL ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. SAUDI ARABIA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. SOUTH AFRICA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. REST OF LAMEA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. BAYER AG: KEY EXECUTIVES
  • TABLE 87. BAYER AG: COMPANY SNAPSHOT
  • TABLE 88. BAYER AG: PRODUCT SEGMENTS
  • TABLE 89. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 90. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 91. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 92. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 93. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 94. CIPLA LTD: KEY EXECUTIVES
  • TABLE 95. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 96. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 97. CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 98. PFIZER INC.: KEY EXECUTIVES
  • TABLE 99. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 100. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 101. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 102. WELLSPRING PHARMACEUTICAL CORPORATION: KEY EXECUTIVES
  • TABLE 103. WELLSPRING PHARMACEUTICAL CORPORATION: COMPANY SNAPSHOT
  • TABLE 104. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT SEGMENTS
  • TABLE 105. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 106. HALEON PLC: KEY EXECUTIVES
  • TABLE 107. HALEON PLC: COMPANY SNAPSHOT
  • TABLE 108. HALEON PLC: PRODUCT SEGMENTS
  • TABLE 109. HALEON PLC: PRODUCT PORTFOLIO
  • TABLE 110. PRESTIGE CONSUMER HEALTHCARE INC.: KEY EXECUTIVES
  • TABLE 111. PRESTIGE CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT
  • TABLE 112. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT SEGMENTS
  • TABLE 113. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT PORTFOLIO
  • TABLE 114. RECKITT BENCKISER GROUP PLC: KEY EXECUTIVES
  • TABLE 115. RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT
  • TABLE 116. RECKITT BENCKISER GROUP PLC: PRODUCT SEGMENTS
  • TABLE 117. RECKITT BENCKISER GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 118. INFIRST HEALTHCARE INC.: KEY EXECUTIVES
  • TABLE 119. INFIRST HEALTHCARE INC.: COMPANY SNAPSHOT
  • TABLE 120. INFIRST HEALTHCARE INC.: PRODUCT SEGMENTS
  • TABLE 121. INFIRST HEALTHCARE INC.: PRODUCT PORTFOLIO
  • TABLE 122. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 123. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 124. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 125. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ANTACIDS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ANTACIDS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN ANTACIDS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALANTACIDS MARKET
  • FIGURE 10. ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR SYSTEMIC ANTACIDS , BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR NON-SYSTEMIC ANTACIDS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. ANTACIDS MARKET, BY FORMULATION TYPE, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR TABLETS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR LIQUIDS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR DRUG STORES AND RETAIL PHARMACIES , BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. ANTACIDS MARKET BY REGION, 2022
  • FIGURE 22. U.S. ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. INDIA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. AUSTRALIA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SOUTH KOREA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. BRAZIL ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SAUDI ARABIA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH AFRICA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF LAMEA ANTACIDS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: ANTACIDS MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2022
  • FIGURE 48. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 50. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. HALEON PLC: NET SALES, 2021-2021 ($MILLION)
  • FIGURE 60. PRESTIGE CONSUMER HEALTHCARE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. RECKITT BENCKISER GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. RECKITT BENCKISER GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. RECKITT BENCKISER GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)